Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia

Leukemia Research Reports

Volumn 3, Issue 2, 2014, Pages 67-69

  Dao, Kim Hien T ^a   Solti, Magdolna B ^b   Maxson, Julia E ^a   Winton, Elliott F ^c   Press, Richard D ^d   Druker, Brian J ^a,d   Tyner, Jeffrey W ^a,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Vancouver Cancer Center   (United States)

^c EMORY UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Atypical chronic myeloid leukemia; Chronic neutrophilic leukemia; Colony stimulating factor 3 receptor; Ruxolitinib

Indexed keywords

HYDROXYUREA; INTERFERON; RUXOLITINIB;

AGED; ANEMIA; ARTICLE; ATYPICAL CHRONIC MYELOID LEUKEMIA; BLOOD CELL COUNT; CANCER THERAPY; CASE REPORT; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG TOLERANCE; GENE FREQUENCY; GENE SEQUENCE; HUMAN; LEUKOCYTOSIS; MALE; PHYSICAL EXAMINATION; QUALITY OF LIFE; SCORING SYSTEM; SPLENOMEGALY; THROMBOCYTOPENIA;

EID: 84907484220     PISSN: 22130489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lrr.2014.07.002     Document Type: Article

References (8)

1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of Tumours) 2008, 441. The International Agency for Research on Cancer, World Health Organization. 4th ed. S. Swerdlow, E. Campo, N. Lee Harris, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
2. Gotlib J., Maxson J.E., George T.I., Tyner J.W. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood 2013, 122(10):1707-1711.
3. Maxson J.E., Gotlib J., Pollyea D.A., Fleischman A.G., Agarwal A., Eide C.A., et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013, 368(19):1781-1790.
4. Pardanani A., Lasho T.L., Laborde R.R., Elliott M., Hanson C.A., Knudson R.A., et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013, 27(9):1870-1873.
5. Mascarenhas J., Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res 2012, 18(11):3008-3014.
6. Fleischman A.G., Maxson J.E., Luty S.B., Agarwal A., Royer L.R., Abel M.L., et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood 2013, 122(22):3628-3631.
7. Emanuel R.M., Dueck A.C., Geyer H.L., Kiladjian J.J., Slot S., Zweegman S., et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012, 30(33):4098-4103.
8. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., Dipersio J.F., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366(9):799-807.